Baglin, Trevor
Centessa Pharmaceuticals plc,
United Kingdom
2024 Rank: 15110
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Cardiovascular System & Hematology
Rank in SubField 1: 543 out of 157372 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 15110 | 16618 |
| Total Cites | 15616 | 16843 |
| H-index | 63 | 65 |
| Hm-index | 26 | 27 |
| Number of Single Authored Papers | 37 | 37 |
| Total Cites to Single Authored Papers | 810 | 857 |
| Number of Single+First Authored Papers | 80 | 80 |
| Total Cites to Single+First Authored Papers | 4248 | 4547 |
| Number of Single+First+Last Authored Papers | 151 | 151 |
| Total Cites to Single+First+Last Authored Papers | 7164 | 7636 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 12820 | 13510 |
| Ratio of Total Citations to Distinct Citing Papers | 1.22 | 1.25 |
| Self-Citation Percentage |
7.28%
|
|
Baglin, Trevor
Medicxi Ventures LLP,
United Kingdom
2023 Rank: 14168
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Cardiovascular System & Hematology
Rank in SubField 1: 525 out of 147556 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 14168 | 15642 |
| Total Cites | 14940 | 16132 |
| H-index | 62 | 64 |
| Hm-index | 26 | 27 |
| Number of Single Authored Papers | 37 | 37 |
| Total Cites to Single Authored Papers | 788 | 835 |
| Number of Single+First Authored Papers | 80 | 80 |
| Total Cites to Single+First Authored Papers | 4130 | 4425 |
| Number of Single+First+Last Authored Papers | 151 | 151 |
| Total Cites to Single+First+Last Authored Papers | 6972 | 7436 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 12245 | 12908 |
| Ratio of Total Citations to Distinct Citing Papers | 1.22 | 1.25 |
| Self-Citation Percentage |
7.39%
|
|
Baglin, Trevor
Medicxi Ventures LLP,
United Kingdom
2022 Rank: 13510
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Cardiovascular System & Hematology
Rank in SubField 1: 514 out of 138599 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 13510 | 14881 |
| Total Cites | 13983 | 15117 |
| H-index | 61 | 63 |
| Hm-index | 25 | 26 |
| Number of Single Authored Papers | 37 | 37 |
| Total Cites to Single Authored Papers | 750 | 797 |
| Number of Single+First Authored Papers | 80 | 80 |
| Total Cites to Single+First Authored Papers | 3926 | 4216 |
| Number of Single+First+Last Authored Papers | 150 | 150 |
| Total Cites to Single+First+Last Authored Papers | 6649 | 7106 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 11414 | 12036 |
| Ratio of Total Citations to Distinct Citing Papers | 1.23 | 1.26 |
| Self-Citation Percentage |
7.50%
|
|
Baglin, Trevor
Medicxi Ventures LLP,
United Kingdom
2021 Rank: 13201
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Cardiovascular System & Hematology
Rank in SubField 1: 499 out of 127911 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 13201 | 14479 |
| Total Cites | 13361 | 14440 |
| H-index | 60 | 62 |
| Hm-index | 25 | 26 |
| Number of Single Authored Papers | 37 | 37 |
| Total Cites to Single Authored Papers | 731 | 778 |
| Number of Single+First Authored Papers | 80 | 80 |
| Total Cites to Single+First Authored Papers | 3757 | 4041 |
| Number of Single+First+Last Authored Papers | 150 | 150 |
| Total Cites to Single+First+Last Authored Papers | 6406 | 6855 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 10902 | 11485 |
| Ratio of Total Citations to Distinct Citing Papers | 1.23 | 1.26 |
| Self-Citation Percentage |
7.47%
|
|
Related Profiles
Featured Profiles
Partner with Us
📢 Reach a targeted audience of science enthusiasts and professionals through our platform. Contact our marketing team:
business@topscinet.com cc: top2percentscientist@gmail.comGet a custom proposal tailored to your banner ad goals.
Partner with Us
📢 Partner with us and reach a targeted audience of science enthusiasts and professionals through our platform. Your company/institute’s banner could be here.